[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-1":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,71,96,126,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100555869","phase-1-safety-and-pharmacokinetics-study-of-pgt121414ls-alone-and-in-combination-with-vrc07-523ls-in-infants-exposed-to-hiv-1-100555869",false,"NCT06517693","Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1","Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1","Inclusion Criteria:\n\n* Birthing parent is of legal age or circumstance to provide independent informed consent and is willing and able to provide written informed consent for themselves and permission for their infant's participation in this study.\n* Birthing parent has confirmed HIV-1 infection based on positive test results from two samples collected from two separate blood collection tubes.\n* Infant was singleton or twin.\n* Infant's gestational age at birth was at least 36 weeks.\n* At birth, infant's weight was at least 2 kg.\n* At entry, infant is less than 72 hours of age and is anticipated to receive study product within 72 hours after birth.\n* At screening, infant has the following laboratory test results:\n\n  * Hemoglobin, normal or grade 1 (≥13 g\u002FdL or ≥8.05 mmol\u002FL)\n  * Platelets, normal or grade 1 (≥100,000 cells\u002Fmm3 or ≥100.000 x10\\^9 cells\u002FL)\n  * Absolute neutrophil count (ANC), normal or grade 1\n\n    1. ≤24 hours old (≥4,000 cells\u002Fmm3 or ≥4.000 x10\\^9 cells\u002FL)\n    2. \\>24 hours old (≥1,250 cells\u002Fmm3 or ≥1.250 x10\\^9 cells\u002FL)\n  * Alanine transaminase (ALT), normal (\\\u003C1.25 x ULN)\n* At entry, infant is generally healthy as determined by the site investigator based on review of all available medical history information and physical examination findings.\n* Cohorts 1 and 2, Strata BF only: At entry, infant is breastfeeding or the birthing parent has indicated an intention to initiate breastfeeding.\n* Cohorts 1 and 2, Strata FF, only: At entry, infant is not breastfeeding and the birthing parent has indicated no intention to breastfeed.\n* At entry, infant is at increased risk of HIV acquisition.\n\nCohorts 1 and 2, Strata FF only:\n\n* Birthing parent had acute HIV during this pregnancy; or\n* Birthing parent with detectable viral replication (plasma HIV RNA results at least 50 copies\u002FmL) during pregnancy who did not have confirmed viral suppression, defined as at least two consecutive plasma HIV RNA results less than 50 copies\u002FmL from specimens obtained at least four weeks apart with the latest result within four weeks prior to delivery; or\n* Birthing parent not receiving appropriate ART for at least two weeks, with any part of the two-week period occurring within four weeks prior to delivery, based on birthing parent's report or available medical records.\n\nCohorts 1 and 2, BF only:\n\n* Per birthing parent's report, intends to breastfeed\n\nExclusion Criteria:\n\n* Birthing parent has received any investigational product during this pregnancy.\n* Infant has received any active or passive HIV immunotherapy or any investigational product.\n* At entry, infant with a documented positive HIV Nucleic Acid Test (NAT) result.\n* Birthing parent or infant has any condition that, in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.",true,"ALL","72 Hours",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.",[27],"HIV-1","RECRUITING","2026-05-27",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2026-01-05",{"date":36,"type":21},"2028-06-30",{"name":38,"class":39},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",17,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100629938","phase-1-inhibiting-the-anti-apoptotic-factor-bcl-2-at-the-time-of-art-initiation-to-promote-apoptosis-of-hiv-infected-cells-and-restrict-the-seeding-of-the-hiv-reservoir-the-initiate-study-100629938","NCT07481175","Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)","Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir: An Investigator-initiated Randomised, Controlled, Open-label Clinical Trial (The INITIATE Study)","INITIATE","Inclusion Criteria:\n\n* Documented HIV-1 infection\n* Age 18-70 years (both included) at screening\n* CD4+ T cell count \\>300\u002FµL at screening\n* ART naïve at screening\n* Able to give informed consent\n* Ability and willingness to provide informed consent and to continue ART throughout the study\n* All participants must agree to use condoms during all sexual intercourse in situations where HIV transmission may still occur, i.e. until fully suppressed on ART (plasma HIV-1 RNA \\\u003C50 copies\u002FmL)\n* All participants must agree not to participate in a conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization, egg donation) during the study\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study.\n* Current or previous use of a BCL-2 antagonist or other pro-apoptotic agent used as cancer therapy\n* Evidence of or strong suspicion that HIV infection was acquired during active PrEP use\n* Any concomitant disease where venetoclax treatment is indicated\n* Current use of any moderate or strong CYP3A4 inhibitors (such as ketoconazole, voriconazole, posaconazole, itraconazole, ritonavir, cobicistat and clarithromycin)\n* Current use of any HIV protease inhibitor (due to CYP3A4 inhibition)\n* Current use of any strong inhibitor of the P-gp drug efflux pump (this includes cobicistat, ritonavir, azithromycin and clarithromycin)\n* Current use of P-gp substrates with narrow therapeutic index (such as such as digoxin, tacrolimus, cyclosporine, sirolimus, dabigatran, colchicine, loperamide)\n* Current use of strong or moderate CYP3A4 inducers (such as carbamazepine, phenytoin, rifampicin, St. John's wort, bosentan, efavirenz and etravirine); intermittent use of moderate CYP3A4 inducers such as modafinil and nafcillin may be used but should be avoided as much as possible\n* Receipt of immunomodulating agents (excluding immunisation) or systemic chemotherapeutic agents within 28 days prior to study entry\n* Any other current or prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study\n* Known hypersensitivity to the components of venetoclax or its analogues\n* Any evidence of an active AIDS-defining opportunistic infection\n* Individuals who intend to modify their ART regimen within the study period\n* Current or recent gastrointestinal disease or gastrointestinal surgery that may impact the absorption of the investigational drug\n* Active alcohol or substance use that, in the Investigator's opinion, will prevent adequate compliance with study therapy or procedures\n* Unable or unwilling to adhere to protocol procedures\n* History of malignancy or transplantation, excluding adequately treated basal cell carcinoma\n* Co-infection with hepatitis B defined as HBsAg-positive or Hepatitis C defined as HCV-RNA positive (Individuals with prior hepatitis B or C infection that is now cleared are eligible for enrolment)\n* For individuals with isolated anti-HBcAb (cleared hepatitis B), the chosen ART regimen must include TDF or TAF\n* Impaired liver function with AST or ALT \\>3 times upper limit of normal\n* Severe hepatic impairment (Class C) as determined by Child-Pugh classification\n* Impaired renal function with estimated creatinine clearance (eGFR) \\\u003C50 mL\u002Fmin\n* Significant cardiac dysfunction\n* Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy as specified in the inclusion criteria\n* The following laboratory values at screening (lab tests may be repeated, as clinically indicated, to obtain acceptable values before failure at screening is concluded but supportive therapies are not to be administered within the week prior to screening tests): Platelet count ≤100 x109\u002FL, Absolute neutrophil count ≤1.0x109\u002FL, Haemoglobin \\\u003C10,0 g\u002FdL, CD4+ T cell count \\\u003C300 cells\u002FuL","18 Years","70 Years",{"count":52,"type":21},38,[24],"Combination therapy with antiretroviral medication (ART) has proven effective in keeping HIV suppressed and restoring the immune system, but it cannot cure the infection. Therefore, lifelong treatment is necessary. The reason for this is a reservoir of inactive virus that remains hidden in long-lived cells and cannot be eliminated by either HIV treatment or the immune system. This reservoir is the primary barrier to a cure for HIV and must be minimized or eliminated in order to make it possible to discontinue lifelong ART treatment.\n\nSeveral studies have been conducted with the aim of reducing the reservoir of inactive virus. The drugs used have been able to activate the virus in resting infected cells, thereby making the virus visible to the immune system. Unfortunately, this type of experimental treatment has not been sufficient to reduce the reservoir of inactive HIV in long-lived cells, possibly because these cells do not undergo cell death to a sufficient degree due to specific alterations in the mechanisms of cell death signaling.\n\nThe drug venetoclax (Venclyxto) is an inhibitor of BCL-2 (B Cell Lymphoma-2), a key factor involved in the regulation of programmed cell death. Studies have shown increased BCL-2 activity in long-lived cells infected with HIV. In laboratory experiments, we have demonstrated that treating cells with venetoclax while simultaneously activating HIV can lead to the elimination of HIV-infected cells. In experiments with HIV-infected humanized mice receiving ART, we further found that treatment with venetoclax delayed viral rebound after interruption of ART compared with mice that were not treated with venetoclax.\n\nThe purpose of this study is to investigate whether treatment with venetoclax in people with HIV who are initiating HIV therapy can promote the death of latently infected cells and thereby lead to a reduction in the latent HIV reservoir. The study will examine the safety and the effect of venetoclax.",[27],[57,58,59],"venetoclax","bcl-2 inhibitor","anti-apoptotic protein","2026-05-01",{"date":62,"type":32},"2026-05-07",{"date":64,"type":32},"2026-04-13",{"date":66,"type":21},"2030-01",{"name":68,"class":69},"Thomas Aagaard Rasmussen","OTHER",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":70},"100535482","early-phase-1-cmv-specific-hiv-car-t-cells-as-immunotherapy-for-hivaids-100535482","NCT06252402","CMV-specific HIV-CAR T Cells as Immunotherapy for HIV\u002FAIDS","A Pilot Study to Evaluate the Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age at the time of screening;\n* Karnofsky Performance Status (KPS) ≥ 70;\n* Documented HIV-1 infection anytime prior to study entry.;\n* On stable ART with undetectable HIV-1 RNA (i.e \\\u003C 20 copies \u002FmL) for at least 48 weeks prior to screening (2 plasma HIV-1 RNA blips 25-200 copies\u002FmL are allowable);\n* CD4+ cell count ≥ 450 cells\u002FμL;\n* Adequate organ function;\n* Willingness to interrupt ART regimen for 4 days prior to leukapheresis;\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Concurrent illness or comorbid condition;\n* History of resistance to two or more classes of antiretroviral drugs;\n* History of prior receipt of an experimental HIV-1, immunotherapeutic agent, or gene therapy product.",{"count":79,"type":21},15,[81],"EARLY_PHASE1","Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and saves lives. Nevertheless, ART cannot eradicate latent cellular reservoirs of the virus, and HIV-1 infection remains a life-long battle. Adoptive cellular immunotherapy using chimeric antigen receptor (CAR) engineered T cells directed against HIV-1 envelope subunit protein gp120 (HIVCAR T cells) may provide a safe and effective way to eliminate HIV-infected cells.\n\nHowever, the number of HIV-infected cells is low in participants under ART, and CAR T cells disappear if they are not stimulated by their target antigens. Interestingly, about 95% of HIV-1-infected individuals are CMV-seropositive and CMV-specific T cells have been shown to persist. To overcome the CAR T cells low persistence issue, we propose to make HIV-CAR T cells using autologous cytomegalovirus (CMV)-specific T cells, which can be stimulated by endogenous CMV in vivo. The overall hypothesis of this first-in-human Phase 1, open-label, single-arm study is that endogenous immune signals to CMV-specific T cells can maintain the presence of autologous bispecific CMV\u002FHIV-CAR T cells in healthy people living with HIV-1 (PLWH), and achieve long-term remission in the presence of ART.",[27],[85,86],"HIV-1, PLWH (Healthy People Living with HIV-1) autologus","CMV-specific T cells, anti-retroviral therapy (ART), Immunotherapy","2026-02-20",{"date":89,"type":32},"2026-02-23",{"date":91,"type":32},"2024-12-19",{"date":93,"type":21},"2026-12-11",{"name":95,"class":69},"City of Hope Medical Center",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":104,"minAge":49,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100590464","phase-4-switch-to-dolutegravir-plus-lamivudine-dual-therapy-in-transgender-women-living-with-hiv-on-virologically-suppressive-antiretroviral-therapy-trans-switch-100590464","NCT06967753","Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)","Switch to Dolutegravir Plus Lamivudine Dual-therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)","TRANS-SWITCH","Inclusion Criteria:\n\n1. 18 years or older at the time of signing the informed consent.\n2. Self-identified as TGW.\n3. Documented HIV-1 infection as per local standard: HIV-1 positive serology by at least two different serological tests (rapid test, ELISA, Western Blot) or a plasma HIV RNA viral ≥1,000 copies\u002FmL.\n4. ART-experienced participant on uninterrupted, stable, and suppressive triple ART for at least 3 months prior to screening, including: a) Acceptable stable ART regimens prior to Screening include 2 NRTIs plus i) INSTI ii) NNRTI or iii) Boosted PI. b) Any prior switch, defined as a change of a single drug or multiple drugs, must have occurred due to tolerability and\u002For safety concerns or access to medications, or convenience\u002Fsimplification and must not have been done for suspected or established treatment failure. The following switches, if they are the only switches, would not be considered a change in regimen. a) A switch from a PI boosted with ritonavir (RTV) to the same PI boosted with cobicistat is allowed (and vice versa). b) A switch from 3TC to emtricitabine (FTC) (and vice versa). c) A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) (and vice versa).\n5. Documented evidence of at least two HIV-1 RNA pVL \\\u003C50 copies\u002FmL in the last 12 months. HIV-1 RNA pVL corresponding to the screening visit may be accepted as second measurement.\n6. Evidence of HIV-1 RNA pVL \\\u003C50 copies\u002FmL at screening visit.\n7. Do not have history of previous virological failure and\u002For evidence of resistance to DTG or 3TC as per protocol definition.\n8. Participants must be able to understand and comply with protocol.\n9. Written informed consent provided.\n\nExclusion Criteria:\n\n1. History or presence of hypersensitivity to any of the study drugs or their components.\n2. Evidence of known acute or chronic viral hepatitis B (positive Hepatitis B surface antigen \\[HBsAg\\]) or hepatitis C (detectable plasma HCV RNA viral load). Participants with chronic Hepatitis B (positive HBsAg) or Hepatitis C (positive plasma HCV RNA viral load) will be excluded. Individuals with evidence of previous Hepatitis B (positive for Hepatitis B core antibody \\[HBcAc\\] but negative HBsAg may be included on the trial. Individuals with positive anti-HCV antibodies but with non-detectable plasma HCV RNA (previously treated or spontaneously cleared HCV) may be included in the study.\n3. Evidence of untreated syphilis infection (positive VDRL at screening without clear documentation of treatment). Participants who are at least 7 days post completed treatment are eligible.\n4. Evidence of an active centers for disease control and prevention (CDC) Stage 3 disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical or current CD4 cell counts less than 200 cells\u002Fmillimeter are not exclusionary. Those individuals who are stable and receiving appropriate treatment for an HIV\u002FAIDS-associated disease can be considered for the study.\n5. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma, or anal or penile intraepithelial neoplasia.\n6. Participants with severe hepatic impairment (Class C) as determined by Child Pugh classification.\n7. Any evidence of preexisting viral resistance based on the presence of any NRTI or INSTI major resistance associated mutation as per IAS-USA 2022 resistance panel in any historical resistance test result. 3TC resistance is considered in the presence of the M184V\u002FI and\u002For K65R and\u002For Q151M mutations. DTG resistance is considered in the presence of the G118R, E138A\u002FK\u002FTG140A\u002FC\u002FR\u002FS, Q148H\u002FK\u002FR, S153F\u002FY, N155H, or R263K mutations.\n8. Participants who, as per the investigator's judgment, poses a significant suicidality risk. Recent history of suicidal behavior and\u002For suicidal ideation may be considered as evidence of serious suicide risk.\n9. Receiving other medications with relevant interactions with DTG and\u002For 3TC.\n10. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening.\n11. Treatment with any of the following agents within 28 days of screening: radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant.\n12. Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of the study drug.\n13. Laboratory tests performed at the screening visit show any of the following results: a. Any verified Grade 4 laboratory abnormality. b. Hemoglobin \\\u003C9.0 g\u002FdL c. Absolute neutrophil count \\\u003C750 cel\u002FµL d. Platelet count \\\u003C80,000 cel\u002Fmm3 e. Creatinine clearance \\\u003C30 mL\u002Fmin according to the Cockroft-Gault formula. f. Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN) or ALT ≥3 times ULN and bilirubin ≥1.5 times ULN (with \\>35% direct bilirubin).\n14. Any condition (including but not limited to the abuse of alcohol or drugs) which in the opinion of the investigator could compromise the participant's safety or adherence to the protocol.","MALE",{"count":106,"type":21},50,[108],"PHASE4","This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.",[111,27],"HIV",[113,114,115],"dual therapy","dolutegravir","antiretroviral treatment","2025-09-05",{"date":118,"type":32},"2025-09-12",{"date":120,"type":32},"2025-07-31",{"date":122,"type":21},"2027-02",{"name":124,"class":69},"UBATEC",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100602365","real-world-effectiveness-of-bictegraviremtricitabinetenofovir-alafenamidebicftctaf-in-plwh-in-precarity-settings-in-france--imea073-100602365","NCT07122557","Real World Effectiveness of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide(BIC\u002FFTC\u002FTAF) in PLWH in Precarity Settings in France -IMEA073","Real World Effectiveness of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide(BIC\u002FFTC\u002FTAF) in PLWH in Precarity Settings in France","PRECARITY","Inclusion Criteria:\n\n* HIV-1 infected patients \\> 18 years during the observation period\n* PLWH with C2S or AME heath insurance coverage information available during the observation period\n* Treatment naive (TN) on BIC\u002FFTC\u002FTAF OR Treatment experienced virologically suppressed (VS TE) or virologically unsupressed (VU TE) in 2d line BIC\u002FFTC\u002FTAF\n* Had at least one follow-up visit after baseline\n\nExclusion Criteria:\n\n* Missing information regarding health insurance coverage\n* On regimen other than BIC\u002FFTC\u002FTAF",{"count":135,"type":21},320,"OBSERVATIONAL","In France, French citizens with an annual income less than 10339 euros are considered living with low-income and are eligible to benefit from a public universal healthcare insurance coverage called C2S (complémentaire santé solidaire). C2S covers primary care and hospital care. Non-citizens with low income, like some migrants, can also benefit from a public healthcare insurance coverage called AME (\"Aide Medicale d'Etat\" for State Medical Aid). These criteria are used as a marker of precarity settings (i.e., socio-economic vulnerability) in France. In France, HIV-related care and treatments are reimbursed at 100% (ALD30), whatever the level of precariousness. ART adherence has been shown significantly lower in PLWH with C2S health insurance coverage. Although BIC\u002FFTC\u002FTAF is a recommended preferred option in naive PLWH and in switch or maintenance therapy in most settings, due to the forgiveness profile and the high genetic barrier to resistance, boosted darunavir (DRV\u002Fr) remains even more widely used than 2nd generation InSTIs in populations in precarity settings, and Real World Effectiveness (RWE) with BIC\u002FFTC\u002FTAF is missing to better support its use in these settings.\n\nParis Bichat Hospital (located in one of the poorest districts in the Ile-de-France region) and Nantes university hospital (West France region) follow a cohort of PLWH with a high proportion of populations in precarity settings (i.e with C2S and AME health insurance coverage): Paris Bichat hospital: N=5143 PLWH (December 2021), sex ratio F\u002FM 37\u002F56%, Transgender Women 7%, and born in sub-Saharan African countries 49%. Nantes university hospital: N=2227 PLWH (December 2021), sex ratio F\u002FM 35\u002F65% and born in sub-Saharan African countries 33%. In this cohort of 7370 PLWH in both sites 50% are receiving an InSTI-based ART regimen, regardless of prior treatment history, and at least 40% are receiving care through the C2S or AME, respectively.",[27,139,140,141],"Public Universal Healthcare Insurance Coverage","BIC\u002FFTC\u002FTAF","Low Income Population","NOT_YET_RECRUITING","2025-08-07",{"date":145,"type":32},"2025-08-14",{"date":147,"type":21},"2025-09",{"date":149,"type":21},"2025-12",{"name":151,"class":69},"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":125},"100551316","viral-infection-of-hspc-impacts-hematopoiesis-100551316","NCT06458504","Viral Infection of HSPC Impacts Hematopoiesis","Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors","MEGAHOST","Inclusion Criteria:\n\nHIV patients :\n\n* HIV-positive patients with a negative or positive viral load.\n* managed at Ambroise Paré Hospital.\n* patients with a bone marrow biopsy or myelogram performed as part of their care.\n\nHealthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.\n\nManagement at Ambroise Paré Hospital.\n\nExclusion Criteria:\n\n\\-",{"count":161,"type":21},45,"We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.",[27,164],"SARS-CoV-2",[27,164,166,167,168],"Hematopoietic Progenitors","Virus-induced","Immunosuppression","2025-03-17",{"date":171,"type":32},"2025-03-20",{"date":173,"type":32},"2024-10-25",{"date":175,"type":21},"2026-03",{"name":177,"class":69},"Assistance Publique - Hôpitaux de Paris"]